Republican lawmakers in the House have introduced a bill Tuesday that tightens eligibility and public reporting requirements within the 340B Drug Discount Program, earning the applause of industry ...
The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...
When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...
In a letter last week, Johnson & Johnson informed certain hospitals of a major change it plans to make in the way it gives out discounts on two drugs. The company has found itself in opposition to ...
The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...
On January 7, 2026, the First Circuit Court of Appeals denied the federal government’s emergency motion to stay a district court injunction blocking implementation of HRSA’s 340B Rebate Model Pilot ...
The Trump administration is pushing significant changes to the healthcare status quo that it says will save money, improve oversight and make the $4.9 trillion sector more efficient. Many of the HHS’ ...
Bristol-Myers Squibb has become the latest drugmaker in the US to file a legal challenge to a block on a drug rebate model opposed by a Health and Human Services (HHS) department. Specifically, BMS is ...
More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results